GPR17 and Dravet syndrome: Based on the observed dysfunctions in the pattern of myelination accompanied by reduced GPR17 expression in brains from a mouse model of DS (see section Involvement of the Purinergic System in Brain Alterations Observed in Down Syndrome), it can be speculated that the pharmacological manipulation of this receptor could prove effective in reducing DS-linked intellectual disabilities.